Tiziana Receives $3.4 Million in Non-Dilutive Funding
June 28, 2024 11:01 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative...
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
June 26, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
June 11, 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
June 11, 2024 08:00 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
May 28, 2024 08:00 ET
|
Neurona Therapeutics
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
UsAgainstAlzheimer’s Launches 2024 Brain Health Academy
April 16, 2024 10:48 ET
|
UsAgainstAlzheimer's
WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- UsAgainstAlzheimer’s today announced the return of its Brain Health Academy, scheduled to begin on May 9, 2024. First launched in 2022, the Academy...
Congress Passes Bills Making Major Investments in Alzheimer’s
March 23, 2024 10:15 ET
|
UsAgainstAlzheimer's
Congress passes major investments in the fight against Alzheimer’s.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
March 11, 2024 08:05 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s
March 08, 2024 07:55 ET
|
UsAgainstAlzheimer's
WASHINGTON, March 08, 2024 (GLOBE NEWSWIRE) -- The maker of donanemab, Eli Lilly, announced today that the Food and Drug Administration (FDA) will convene an advisory committee to consider the...
Global Neurological Biomarkers Market Analysis Report 2024-2030 - CAGR of 12.8% - Increased Funding For R&D in Biomarkers to Boost Development of New Drugs
January 24, 2024 05:40 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Neurological Biomarkers Market Size, Share & Trends Analysis Report by Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism),...